A glycolysis-related gene pairs signature predicts prognosis in patients with hepatocellular carcinoma

PeerJ

article

Weige Zhou¹  Shijing Zhang¹  Zheyou Cai¹  Fei Gao²  Wenhui Deng³  Yi Wen⁴  Zhen-wen Qiu⁴  Zheng-kun Hou⁴  Xin-Lin Chen¹ 

[1] School of Basic Medical Science, Guangzhou University of Chinese Medicine;Department of Minimally Invasive & Interventional Radiology, Sun Yat-sen University Cancer Center;The Fourth Affiliated Hospital of Guangzhou University of Chinese Medicine;The First Affiliated Hospital of Guangzhou University of Chinese Medicine

关键词: Glycolysis;    Hepatocellular carcinoma;    GRGPs signature;    Prognosis;    mRNAs;   

DOI  :  10.7717/peerj.9944

学科分类：社会科学、人文和艺术（综合）

来源: Inra

【 摘 要 】

Background Hepatocellular carcinoma (HCC) is one of the most universal malignant liver tumors worldwide. However, there were no systematic studies to establish glycolysis‑related gene pairs (GRGPs) signatures for the patients with HCC. Therefore, the study aimed to establish novel GRGPs signatures to better predict the prognosis of HCC. Methods Based on the data from Gene Expression Omnibus, The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium databases, glycolysis-related mRNAs were used to construct GRGPs. Cox regression was applied to establish a seventeen GRGPs signature in TCGA dataset, which was verified in two validation (European and American, and Asian) datasets. Results Seventeen prognostic GRGPs (HMMR_PFKFB1, CHST1_GYS2, MERTK_GYS2, GPC1_GYS2, LDHA_GOT2, IDUA_GNPDA1, IDUA_ME2, IDUA_G6PD, IDUA_GPC1, MPI_GPC1, SDC2_LDHA, PRPS1_PLOD2, GALK1_IER3, MET_PLOD2, GUSB_IGFBP3, IL13RA1_IGFBP3 and CYB5A_IGFBP3) were identified to be significantly progressive factors for the patients with HCC in the TCGA dataset, which constituted a GRGPs signature. The patients with HCC were classified into low-risk group and high-risk group based on the GRGPs signature. The GRGPs signature was a significantly independent prognostic indicator for the patients with HCC in TCGA (log-rank P = 2.898e−14). Consistent with the TCGA dataset, the patients in low-risk group had a longer OS in two validation datasets (European and American: P = 1.143e−02, and Asian: P = 6.342e−08). Additionally, the GRGPs signature was also validated as a significantly independent prognostic indicator in two validation datasets. Conclusion The seventeen GRGPs and their signature might be molecular biomarkers and therapeutic targets for the patients with HCC.

【 授权许可】

CC BY